Vraylar clinical uses
Pro Research Analysisby 
Searched over 200M research papers
Vraylar (Cariprazine) Clinical Uses: Schizophrenia, Bipolar Disorder, and Depression
Schizophrenia Treatment with Vraylar
Vraylar (cariprazine) is approved for the treatment of schizophrenia in adults. Clinical trials have shown that Vraylar is more effective than placebo in reducing symptoms of schizophrenia, including both positive and negative symptoms, and in delaying relapse. It has also demonstrated greater efficacy than risperidone in improving negative symptoms in patients with predominantly negative symptoms of schizophrenia, a group that is often difficult to treat. Most side effects are mild to moderate, and metabolic changes are generally not clinically significant. However, there is a boxed warning for increased risk of death in elderly patients with dementia-related psychosis, which is not an approved use for the drug 2De Deurwaerdère2016McCormack2015+3 MORE.
Bipolar Disorder: Mania, Mixed Episodes, and Bipolar Depression
Vraylar is also approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Clinical trials have shown that it is more effective than placebo in reducing symptoms during these episodes. Additionally, Vraylar has received expanded approval for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults. In clinical studies, Vraylar demonstrated significant improvements in depression rating scales compared to placebo, particularly at doses of 1.5 mg and 3 mg 12De Deurwaerdère2016+2 MORE.
Adjunctive Treatment for Major Depressive Disorder (MDD)
Recently, the FDA approved Vraylar as an adjunctive treatment for major depressive disorder (MDD) in adults. This means it can be used alongside other antidepressant medications to help improve symptoms in patients who do not respond adequately to standard treatments .
Summary of Clinical Indications
- Schizophrenia in adults
- Acute treatment of manic or mixed episodes in bipolar I disorder
- Treatment of depressive episodes in bipolar I disorder (bipolar depression)
- Adjunctive treatment for major depressive disorder (MDD) in adults
Conclusion
Vraylar (cariprazine) is a versatile antipsychotic medication with established clinical uses in the treatment of schizophrenia, bipolar I disorder (including mania, mixed episodes, and bipolar depression), and as an adjunctive therapy for major depressive disorder in adults. Its effectiveness in treating both positive and negative symptoms of schizophrenia, as well as its role in mood disorders, makes it a valuable option for clinicians managing these challenging psychiatric conditions 12De Deurwaerdère2016+5 MORE.
Sources and full results
Most relevant research papers on this topic